History

In 1933 Cutting, Mehrtens and Tainter at Stanford published in JAMA describing 2,4-dinitrophenol's metabolic-stimulant and weight-reducing effects, and within roughly a year more than 100,000 Americans had taken it as an over-the-counter slimming agent. Reports of dinitro-cataracts (causing blindness in some users), agranulocytosis, neuropathy and deaths accumulated through the late 1930s, and the 1938 Federal Food, Drug, and Cosmetic Act gave the FDA expanded authority that effectively ended legal sale; DNP was declared unfit for human consumption and has never been FDA-approved as a drug. It resurfaced via unregulated internet sales as a "fat burner," especially in bodybuilding circles (Geisler 2019).

DNP (2,4-dinitrophenol) is a small synthetic chemical that was briefly sold as a weight-loss drug in the 1930s, was pulled from the market after it blinded and killed people, and has returned through unregulated online sales as an illicit “fat burner.” It is important to be precise about what DNP is and is not: it is not a peptide, not a hormone, not an anabolic-androgenic steroid, and not a SARM. It is a chemical uncoupler of energy metabolism. It is the single most dangerous compound commonly discussed in fat-loss circles, because the same mechanism that burns fat is the mechanism that kills — there is no clean line between the two. This page is educational and harm-reduction oriented and contains no dosing, cycles, or sourcing information.

What it is

DNP is a small synthetic aromatic compound — a substituted phenol — historically used as a dye intermediate, wood preservative, and pesticide. Pharmacologically it is a protonophore, a chemical uncoupler of oxidative phosphorylation. As a lipophilic weak acid, it carries protons (H+) across the inner mitochondrial membrane, dissipating the proton-motive gradient that mitochondria normally use to make ATP. The electron transport chain keeps running, but the energy is released as heat instead of being captured as ATP. To compensate, the cell burns more fuel at an accelerated rate, raising basal metabolic rate and core body temperature. That is why it produces rapid fat loss — and why an overdose produces uncontrollable hyperthermia (Geisler 2019; Grundlingh 2011). It is not a hormone, not a steroid, and not a peptide.

The claims

In bodybuilding and “biohacking” circles, DNP is promoted for rapid, aggressive fat loss, valued precisely because it works largely independent of diet and exercise — it raises the body’s metabolic rate directly. It is most often discussed for pre-contest cutting. There is no legitimate medical use of raw DNP in humans today. (Separately, Mitochon Pharmaceuticals held an open FDA Investigational New Drug application for a controlled-release DNP analog, MP101, being studied for neurodegenerative disease — but that is an investigational research pathway, not an approval, and not the same thing as the illicit oral DNP sold online.)

What the evidence actually shows

The honest summary is that there is no modern controlled human evidence establishing DNP as a safe or effective weight-loss agent. The “evidence” base is the uncontrolled clinical use of the 1930s plus modern self-reports and toxicology data — and that toxicology data is a record of harm.

No modern controlled efficacy or safety trials in humans exist.
Grundlingh et al. 2011 (review) catalogued 62 published deaths attributable to DNP up to that point and characterized it as having “an unacceptably high rate of significant adverse effects.” The acute toxidrome is hyperthermia, tachycardia, tachypnea, diaphoresis, and metabolic acidosis.
Case reports consistently show death from runaway hyperthermia and ATP depletion, often within hours. The Hermetet et al. 2024 fatal case (a 21-year-old bodybuilder) measured a blood DNP of 88 mg/L, with hair analysis confirming chronic use alongside anabolic steroids.
Lindeman et al. 2025, a two-case series in Toxicology Reports, documented progression to respiratory acidosis, severe hyperkalemia, hyperthermia, and peri-mortem rigidity from catastrophic ATP loss — proposing a “runaway uncoupling” self-amplifying mechanism.

There is no body of evidence supporting DNP as a defensible fat-loss tool. What exists is a consistent literature of fatal poisoning.

Legal and regulatory status

US — never FDA-approved for humans. DNP has never been approved by the FDA for human consumption, and sale for human use is illegal and actively prosecuted. US distributors have received multi-year federal prison sentences — for example, a 7-year maximum sentence for one online seller (the operator of CrystalDNP.com, linked to two customer deaths). The FDA acted against 110 DNP-selling websites during International Operation Pangea IX (2016).

Not a controlled substance. DNP is not scheduled under the federal Controlled Substances Act. Its illegality flows from being an unapproved, misbranded drug sold for human use, not from drug scheduling. (This is a contrast worth noting: anabolic steroids such as mesterolone and fluoxymesterone — sometimes named alongside DNP — are Schedule III; fluoxymesterone retains narrow FDA-approved indications. Insulin, aromatase inhibitors, SERMs, and T3 are prescription drugs but not controlled substances. DNP belongs to none of those categories.)

Anti-doping (WADA 2026). DNP is not specifically named on the WADA Prohibited List as of 2026 (verified against the 2026 list and the USADA 2026 changes advisory). The only newly added uncoupler-class metabolic agent for 2026 is BAM15, which WADA/USADA classify as an AMPK activator under S4 (Hormone and Metabolic Modulators), not as DNP; a second 2026 S4 addition is the aromatase inhibitor α-naphthoflavone. DNP itself is not enumerated on the list. That absence is a technicality, not a safety endorsement — any unapproved metabolic uncoupler should be treated as high-risk, and an athlete using one is taking a substance with no medical clearance whatsoever.

Safety

DNP is the most dangerous compound commonly discussed for fat loss, and the reason is structural: its therapeutic mechanism and its killing mechanism are identical. There is no ceiling separating a “fat-loss dose” from a lethal dose, the margin is narrow and unpredictable between individuals and between batches (illicit product is unstandardized), and there is no antidote.

Acute lethal syndrome: uncontrollable hyperthermia (core temperatures that can exceed 40–44°C), tachycardia, tachypnea, profuse sweating, agitation, rhabdomyolysis, hyperkalemia, metabolic acidosis, seizures, and then cardiovascular collapse. Death can occur within hours.
No specific reversal therapy exists. Once uncoupling is severe, even maximal cooling and supportive ICU care frequently fail. Dantrolene has been proposed as an adjunct (Kopec et al. 2019) on the theory it may lessen excitation-contraction coupling and hyperthermia, but the evidence is limited to case-level observation — it is not an established or reliable rescue.
Chronic effects: cataracts (which historically blinded users), peripheral neuropathy, agranulocytosis, hepatotoxicity, and skin and eye injury.
Hallmark non-fatal signs of use reported by users include excessive sweating, heat intolerance, lethargy, and yellow-stained skin and sweat.

For context, the prescription compounds sometimes grouped with DNP carry their own serious risks — non-diabetic insulin misuse can cause fatal hypoglycemia, seizures, and permanent brain injury; aromatase inhibitors drive bone-density loss and adverse lipid changes; SERMs raise clot/venous-thromboembolism risk; T3 (liothyronine) can cause iatrogenic thyrotoxicosis, atrial fibrillation, and bone loss. But none of those approach DNP’s combination of a razor-thin dose margin and the complete absence of an antidote.

Bottom line

DNP is uniquely lethal among “fat-loss” compounds because the mechanism that produces weight loss is the same mechanism that produces fatal hyperthermia — the dose margin is razor-thin, the supply is unregulated and unstandardized, and there is no antidote. It is not a peptide and not a steroid; it is a mitochondrial uncoupler. It has never been FDA-approved for human use, it is illegal to sell for human consumption (and prosecuted), and although it is not specifically named on the WADA list, it is wholly unsafe and indefensible for performance or weight-loss use. People who take it die, and they die quickly and without a reliable rescue.

Evidence grade: No credible evidence. (No modern controlled human evidence supports safe or effective use; the human record consists of fatal poisonings.)

DNP (2,4-Dinitrophenol)